drugset / Trial / NCT04225260
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Timeline
- Start
- 2020-01-27
- Primary completion
- 2021-04-12
- Completion
- 2021-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin | Protein / enzyme biologic | — | Other |